Skip to main content

ERRATUM article

Front. Pharmacol., 06 June 2016
Sec. Experimental Pharmacology and Drug Discovery
Volume 7 - 2016 | https://doi.org/10.3389/fphar.2016.00165

Erratum: Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach

This article is an erratum on:

  1. Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach

    1. Read original article
\r\nFrontiers Production Office*Frontiers Production Office*
  • Frontiers Production Office, Frontiers, Lausanne, Switzerland

An erratum on
Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach

by Platania, C. B. M., Di Paola, L., Leggio, G. M, Romano, G. L., Drago, F., Salomone, S., et al. (2015) Front. Pharmacol. 6:248. doi: 10.3389/fphar.2015.00248

Reason for Erratum:

Due to a typesetting error, the article was published with incorrect values in Table 4. The publisher apologizes for this error and the correct version of Table 4 appears below. This error does not change the scientific conclusions of the article in any way.

TABLE 4
www.frontiersin.org

Table 4. MM-PBSA results compared to experimental binding parameters.

References

Papadopoulos, N., Martin, J., Ruan, Q., Rafique, A., Rosconi, M. P., Shi, E., et al. (2012). Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15, 171–185. doi: 10.1007/s10456-011-9249-6

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: ranibizumab, bevacizumab, aflibercept, diabetic retinopathy, molecular dynamics

Citation: Frontiers Production Office (2016) Erratum: Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach. Front. Pharmacol. 7:165. doi: 10.3389/fphar.2016.00165

Received: 01 June 2016; Accepted: 01 June 2016;
Published: 06 June 2016.

Approved by:

Pharmacology Editorial Office, Frontiers, Switzerland

Copyright © 2016 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, production.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.